慢性乙型肝炎抗病毒治疗进展(6)
[32]Su WW，Hsu CW，Lee CM，et al.Combination therapy with peginterferon alfa-2a and a nucleos(t)ide analogue for HBeAg-positive chronic hepatitis B patients： results of a large randomized， multicentre， double-blind， placebo-controlled study[J].Journal of Hepatology，2014，60(1)：S47.
[33]Petersen J，Ratziu V，Buti M，et al.Entecavir plus tenofovir combination as rescue therapy in pretreated chronic hepatitis B patients： an international multicenter cohort study[J].J Hepatol，2012，56(3)：520-526.
, 百拇医药
[34]Seto WK，Liu K，Fung J，et al.Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir[J].Antivir Ther，2012，17(7)：1255-1262.
[35]Zhao P，Wang C，Huang L，et al.Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B[J].Antiviral Res，2012，96(2)：100-104.
[36]Sun J，Hou JL，Xie Q，et al.Randomised clinical trial：efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance[J].Aliment Pharmacol Ther，2011，34(4)：424-431.
, 百拇医药
[37]岳偉，袁宏，毛小荣，等.不同策略治疗rtN236T位点变异的HBeAg阳性慢性乙型肝炎的疗效观察[J].中华肝脏病杂志，2013，21(3)：184-188.
[38]Reijnders JG，Perquin MJ，Zhang N，et al.Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B[J].Gastroenterology，2010，139(2)：491-498.
[39]Tseng TC，Liu CJ，Su TH，et al.Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation[J].J Infect Dis，2012，206(10)：1521-1531.
, 百拇医药
[40]Bertoletti A，Ferrari C.Innate and adaptive immune responses in chronic hepatitis B virus infections： towards restoration of immune control of viral infection[J].Gut，2012，61(12)：1754-1764.
[41]Boni C，Laccabue D，Lampertico P，et al.Restored function of HBV-specific T-cells after long-term effective therapy with nucleos(t)ide analogues[J].Gastroenterology，2012，143(4)：963-973.
[42]Fisicaro P，Valdatta C，Massari M，et al.Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T-cells against HBV， but not HCV[J].Gastroenterology，2012，143(6)：1576-1585.
, 百拇医药
[43]Ejrnaes M，Filippi CM，Martinic MM，et al.Resolution of a chronic viral infection after interleukin-10 receptor blockade[J].J Exp Med，2006，203(11)：2461-2472.
[44]Tinoco R，Alcalde V，Yang Y，et al.Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo[J].Immunity，2009，31(1)：145-157., 百拇医药(汪晓凤 邵和军)
[33]Petersen J，Ratziu V，Buti M，et al.Entecavir plus tenofovir combination as rescue therapy in pretreated chronic hepatitis B patients： an international multicenter cohort study[J].J Hepatol，2012，56(3)：520-526.
, 百拇医药
[34]Seto WK，Liu K，Fung J，et al.Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir[J].Antivir Ther，2012，17(7)：1255-1262.
[35]Zhao P，Wang C，Huang L，et al.Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B[J].Antiviral Res，2012，96(2)：100-104.
[36]Sun J，Hou JL，Xie Q，et al.Randomised clinical trial：efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance[J].Aliment Pharmacol Ther，2011，34(4)：424-431.
, 百拇医药
[37]岳偉，袁宏，毛小荣，等.不同策略治疗rtN236T位点变异的HBeAg阳性慢性乙型肝炎的疗效观察[J].中华肝脏病杂志，2013，21(3)：184-188.
[38]Reijnders JG，Perquin MJ，Zhang N，et al.Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B[J].Gastroenterology，2010，139(2)：491-498.
[39]Tseng TC，Liu CJ，Su TH，et al.Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation[J].J Infect Dis，2012，206(10)：1521-1531.
, 百拇医药
[40]Bertoletti A，Ferrari C.Innate and adaptive immune responses in chronic hepatitis B virus infections： towards restoration of immune control of viral infection[J].Gut，2012，61(12)：1754-1764.
[41]Boni C，Laccabue D，Lampertico P，et al.Restored function of HBV-specific T-cells after long-term effective therapy with nucleos(t)ide analogues[J].Gastroenterology，2012，143(4)：963-973.
[42]Fisicaro P，Valdatta C，Massari M，et al.Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T-cells against HBV， but not HCV[J].Gastroenterology，2012，143(6)：1576-1585.
, 百拇医药
[43]Ejrnaes M，Filippi CM，Martinic MM，et al.Resolution of a chronic viral infection after interleukin-10 receptor blockade[J].J Exp Med，2006，203(11)：2461-2472.
[44]Tinoco R，Alcalde V，Yang Y，et al.Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo[J].Immunity，2009，31(1)：145-157., 百拇医药(汪晓凤 邵和军)